Extended Data Fig. 3: Kaplan-Meier Estimate for Extracranial Progression-Free Survival, by Cohort.
From: Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
The median time to extracranial progression was 4.5 months (blue line - 90% CI: 1.2-6.7 months) for cohort A and 4.6 months (red line - 90% CI: 2.7-8.1 months) for cohort B.
